stockrow
Friday 6 November 2026
Export XNCR’s income statement to Excel — free account
Xencor, Inc.
XNCR Healthcare Biotechnology
Xencor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $125.6 million, up 13.7% from fiscal 2024.
- Revenue
- +17.5%
- EPS
- +29.3%
- Free cash flow
- −52.9%
Quarter to June 2026, against a year earlier
36.21
2.16
+6.34%
Follow XNCR
Alert me
Xencor, Inc. (XNCR) Revenue
Xencor, Inc.'s revenue for fiscal 2025 was $125.6M, up 13.7% from $110.5M in fiscal 2024. Over the twelve months to 30 June 2026 it was $105.0M. Over the past ten years it has ranged from $27.8M (fiscal 2015) to $275.1M (fiscal 2021); the current reading is higher than 64% of that period. Xencor, Inc. ranks 94th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $125.6M | 13.65% |
| FY2024 | $110.5M | (36.72%) |
| FY2023 | $174.6M | 6.10% |
| FY2022 | $164.6M | (40.18%) |
| FY2021 | $275.1M | 124.23% |
| FY2020 | $122.7M | (21.70%) |
| FY2019 | $156.7M | 285.93% |
| FY2018 | $40.6M | (12.02%) |
| FY2017 | $46.2M | (57.67%) |
| FY2016 | $109.0M | 292.70% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $51.2M | 1,034.21% |
| Mar 2026 | $4.5M | (84.01%) |
| Dec 2025 | $28.2M | 34.47% |
| Sep 2025 | $21.0M | (51.85%) |
| 39 more quarters | Free account |
Against its own ten years
Low $27.8M
High $275.1M
Ten-year median
$122.7M
Current reading's percentile
64
Revenue against peers
| Company | Revenue |
|---|---|
| ADMA ADMA Biologics Inc compare | $519.2M |
| ZLAB Zai Lab Limited Unsponsored ADR compare | $441.7M |
| BEAM Beam Therapeutics Inc. compare | $146.6M |
| XNCR Xencor, Inc. | $105.0M |
| RCUS Arcus Biosciences, Inc. compare | $100.0M |
| RXRX Recursion Pharmaceuticals, Inc. compare | $68.2M |
| NAMS NewAmsterdam Pharma Company N.V. compare | $25.9M |
| PHVS Pharvaris N.V. compare | — |
| MBX MBX Biosciences, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on XNCR
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement